Core Insights - Acrivon Therapeutics has appointed Dr. Mansoor Raza Mirza as the new Chief Medical Officer, effective April 9, 2025, succeeding Dr. Jean-Marie Cuillerot [1][2] - Dr. Mirza will lead the clinical development of Acrivon's ongoing trials, including the Phase 2b trial of ACR-368 for endometrial cancer and the Phase 1 study of ACR-2316 [1][2] - Acrivon is focused on precision medicine through its Acrivon Predictive Precision Proteomics (AP3) platform, which aims to match drug candidates to patients based on predicted sensitivity [1][7] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company specializing in precision oncology medicines [7] - The company utilizes its proprietary AP3 platform to discover and develop drug candidates, measuring compound-specific effects on tumor cell protein signaling networks [7][9] - Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for endometrial cancer [7][8] Clinical Development - ACR-368 has received Fast Track designation from the FDA for its investigation as a monotherapy in endometrial cancer [7] - The ACR-2316 program is also advancing rapidly, showing promising clinical activity during its dose escalation phase [2][8] - Acrivon is developing an OncoSignature test for ACR-368 to identify patients likely to benefit from the treatment, which has received Breakthrough Device designation from the FDA [7] Leadership and Expertise - Dr. Mirza is recognized for his contributions to the clinical development of therapies for ovarian and endometrial cancers, having led multiple successful trials [2][3] - He has authored numerous publications and has been involved in developing national guidelines for managing gynecologic cancers [3][4] - Dr. Mirza's extensive experience includes key positions in various prestigious organizations related to gynecologic oncology [4][5]
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer